IPM Take
Cardiovascular medicine has entered an implementation decade. The science is mature: blood pressure control, lipid management, cardiac rehabilitation, telehealth, prevention, rehabilitation, digital health and team-based care all have evidence behind them. The political problem is that every region is solving a different part of the delivery puzzle. The US is fighting over reimbursement and administrative friction. Europe is building a strategic cardiovascular framework. England is turning CVD into a national performance target. Latin America is scaling protocol-based hypertension control. South-East Asia is pushing regional primary-care implementation. Australia is building chronic disease frameworks while still struggling with cardiac rehabilitation access. The lesson is blunt: cardiovascular policy is not one global race. It is a patchwork of access, payment, workforce and accountability battles.
Executive Summary
The American College of Cardiology’s 2026 mid-year advocacy update highlights a series of US policy wins and unresolved fights. At federal level, ACC reports that Medicare telehealth flexibilities were extended through 31 December 2027, while virtual in-home cardiac and pulmonary rehabilitation services were reinstated through 1 January 2028. The College also cites advocacy around Medicare payment reform, the Ambulatory Specialty Model for heart failure, AI and digital health policy, TAVR coverage, research funding, workforce barriers and clinician well-being.
At state level, ACC chapters reported policy activity on prior authorisation reform, non-compete restrictions for healthcare professionals, AED funding, CPR education, coronary artery calcium testing coverage, self-measured blood pressure monitoring and peripheral artery disease screening.
The US pattern is highly transactional: payment codes, prior authorisation, telehealth rules, state-level prevention laws and clinician workforce protections. By contrast, the European Union has adopted the Safe Hearts Plan, the first EU-level cardiovascular health plan, focused on prevention, early detection and screening, treatment, care and rehabilitation. England’s NHS 10 Year Health Plan and oversight framework link cardiovascular progress to reduced premature mortality from heart disease and stroke, with emphasis on blood pressure and cholesterol management.
In the Americas, PAHO’s HEARTS initiative is pushing a primary-care model for hypertension, diabetes and dyslipidaemia management, with the goal that HEARTS becomes the standard for cardiovascular risk management in primary care across the region by 2027. South-East Asia is using SEAHEARTS to accelerate prevention and control of cardiovascular disease through regional implementation. Australia’s 2026-35 chronic conditions framework emphasises prevention, early intervention, continuity of care, multimorbidity and priority populations, while national cardiovascular policy still faces delivery gaps.
The comparison shows that cardiovascular policy is converging on the same themes: prevention, access, digital infrastructure, rehabilitation, workforce and equity. But the mechanisms remain uneven.
Why it matters
- Policymakers and public authorities: Cardiovascular policy is moving beyond guidelines. The real question is whether laws, strategies and payment systems actually change screening, treatment, rehabilitation and long-term prevention.
- Payers and HTA bodies: Coverage decisions for telehealth, cardiac rehabilitation, blood pressure monitoring, coronary calcium testing, heart failure models and preventive medicines are now core cardiovascular policy tools.
- Clinicians and providers: Cardiology is being pulled into policy debates on prior authorisation, payment reform, workforce shortages, virtual care, AI and team-based prevention. Clinical quality increasingly depends on administrative design.
- Patients and advocates: Access still depends heavily on geography, insurance, income, digital readiness and local political choices. Cardiovascular evidence is global, but access remains local.
- Industry and innovation partners: Digital tools, AI, remote monitoring and diagnostics will only scale if they fit into reimbursed, regulated and equity-tested care pathways.
Cardiovascular policy is no longer only about new drugs, new devices or new guidelines. It is about whether the system can deliver what cardiology already knows works.
The American College of Cardiology’s 2026 mid-year advocacy update captures that shift clearly. The US cardiovascular policy agenda is now crowded with issues that sit outside the cath lab but determine what happens to patients: telehealth reimbursement, cardiac rehabilitation access, prior authorisation, Medicare payment, workforce shortages, AI oversight, research funding and prevention coverage.
This is where modern cardiology is being fought.
In February 2026, ACC advocacy helped secure the extension of Medicare telehealth flexibilities through 31 December 2027 and the reinstatement of virtual in-home cardiac and pulmonary rehabilitation services through 1 January 2028. That matters because cardiovascular care does not end at discharge, and rehabilitation does not help patients who cannot reach it. For rural patients, older adults, working people and those with transport barriers, virtual cardiac rehabilitation is not a convenience. It can be the difference between evidence-based recovery and no recovery pathway at all.
At state level, the US picture is even more fragmented. Kentucky enacted prior authorisation reform. Virginia passed a law banning non-compete agreements for healthcare professionals. Pennsylvania passed a Smart Heart bill after a multi-year campaign. New York and Vermont secured AED funding, while Alaska advanced CPR education legislation. Other state efforts are pushing insurance coverage for coronary artery calcium testing, self-measured blood pressure monitoring and peripheral artery disease screening.
This is the American model: a policy battlefield of coverage, payment, state law, administrative burden and advocacy pressure.
It is messy, but it is concrete.
Europe is moving differently. The European Commission’s Safe Hearts Plan, unveiled in December 2025, is the first EU-level approach to cardiovascular disease. It focuses on prevention, early detection and screening, treatment, care and rehabilitation, with particular attention to vulnerable groups such as women, children and young people. It is a major political signal: cardiovascular disease is finally being treated as a continental health priority, not only a national clinical issue.
But Europe’s risk is the opposite of the US. The plan is strategic, ambitious and coherent. The question is whether Member States will build the machinery. A European cardiovascular plan does not automatically create national screening pathways, pay for rehabilitation, fix workforce shortages, connect data systems or reduce inequalities. Europe has a mandate. Now it needs mechanisms.
England sits somewhere between the two models. The NHS 10 Year Health Plan is built around three shifts: hospital to community, analogue to digital, and sickness to prevention. Cardiovascular disease is central to this logic. NHS planning has linked heart disease and stroke prevention to the ambition of reducing premature mortality, with particular emphasis on better management of blood pressure and cholesterol. That is a more operational approach than broad strategy alone: it names the risk factors that need control and ties them to system performance.
The question for England is whether prevention survives pressure from waiting lists, workforce shortages and hospital demand. Everyone says prevention is cheaper than crisis care. Far fewer systems fund it like they believe it.
The Americas offer another model: protocol-driven primary care. PAHO’s HEARTS in the Americas initiative aims for the HEARTS model to become the standard for cardiovascular risk management, including hypertension, diabetes and dyslipidaemia, in primary care across the region by 2027. This is not glamorous policy. It is standardised treatment protocols, validated blood pressure measurement, team-based care, medicines access, data feedback and quality improvement.
That may be exactly why it matters.
Hypertension control is one of the least mysterious problems in cardiovascular medicine and one of the most neglected. PAHO’s HEARTS Quality Framework is designed to strengthen hypertension and cardiovascular risk management in primary care and has been presented as a way to prevent hundreds of thousands of deaths by 2030. The Americas are showing that cardiovascular policy does not always need another summit. Sometimes it needs a blood pressure cuff, a protocol, a nurse, a pharmacist, a medicine supply chain and a dashboard.
South-East Asia is pursuing a regional version of that logic. WHO’s SEAHEARTS initiative is designed to accelerate prevention and control of cardiovascular diseases across the South-East Asia Region. The emphasis is on implementing a regional resolution, strengthening primary care and scaling practical cardiovascular prevention tools. India’s hypertension control work shows what this can look like in practice: protocol-based treatment, improved medicine availability and reduced out-of-pocket medicine costs have been reported as key levers for better blood pressure control.
For lower- and middle-income settings, this is the policy lesson: cardiovascular prevention cannot depend on specialist-heavy care models. It has to be built into primary care, procurement, workforce training and medicine access.
Australia has a different problem. It has national strategies and strong clinical expertise, but delivery gaps remain visible. The National Strategic Action Plan for Heart Disease and Stroke provides a roadmap focused on prevention and early detection, diagnosis and treatment, support and care, and research. The newer National Strategic Framework for Chronic Conditions 2026-35 emphasises prevention, early intervention, continuity of care, multimorbidity and priority populations. Yet recent Australian evidence on cardiac rehabilitation shows how hard implementation remains: services exist, evidence exists, but referral and attendance remain too low.
Canada offers a quality-standard approach in some jurisdictions. Ontario Health’s 2026 operational standards for outpatient cardiovascular rehabilitation are an example of moving from “rehabilitation is important” to defining what programmes should actually deliver. That matters because cardiovascular care quality cannot improve if services are not measured, standardised and accountable.
Taken together, the global comparison is revealing.
The US is legislating and litigating the access mechanics. Europe is setting a continental strategy. England is trying to turn prevention into NHS redesign. Latin America is building primary-care implementation through HEARTS. South-East Asia is scaling region-wide prevention. Australia is aligning chronic disease policy while facing real-world cardiac rehabilitation gaps. Canada is using standards to define service quality.
Different routes. Same problem.
Cardiovascular disease is not waiting for policy systems to become elegant. It is exploiting every weak point: untreated hypertension, uncontrolled cholesterol, missed rehabilitation, unaffordable medicines, poor follow-up, workforce burnout, fragmented data and administrative delay.
The ACC update is important because it shows that advocacy is no longer peripheral to cardiology. It is part of care delivery. Prior authorisation policy affects whether patients receive treatment. Telehealth policy affects whether rehabilitation reaches people. Payment reform affects whether clinicians can spend time on prevention. Workforce law affects whether services can staff clinics. AI policy affects whether digital tools help patients or create new risks.
The global lesson is blunt: cardiovascular health is now a governance test.
Regions that treat CVD as a narrow clinical issue will keep paying for preventable events. Regions that connect policy, reimbursement, primary care, rehabilitation, data and equity may finally bend the curve.
The future of cardiology will not be decided only by what is discovered in trials.
It will be decided by whether governments can turn evidence into access.
